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INTRODUCTION
The euthyroid sick syndromes (ESS) refer to changes in thy-
roid hormone metabolism and regulation in the patients with
nonthyroidal illness (1). The observed abnormalities are usually
reversible and have been attributed to disturbances in peripheral
metabolism, tissue uptake, binding, and receptor occupancy
of thyroid hormones. The hypothalamic-pituitary-thyroid axis
could be suppressed in more severe and prolonged nonthy-
roidal illness (2-9). Despite the description of the syndrome
some 38 yr ago, its pathogenesis remains elusive. Recently,
particular attention was paid to the role of cytokines in the
pathogenesis of ESS. It is currently agreed that ESS is related
with an increased production of cytokines, but the degree of
cytokine involvement and their specific role in the pathogenesis
of ESS remain to be elucidated. 
Bone marrow transplantation (BMT) is currently the treat-
ment of choice for many hematologic diseases. Thyroid dys-
function is one of the most common endocrine abnormalities
occurring after BMT. Among the patients undergoing BMT,
the development of ESS indicates a poor prognosis. There have
been several studies regarding the change of thyroid function
following BMT. However, there were few studies about the
relation of thyroid hormone changes and cytokines in the
patients undergoing BMT. We previously reported negative
relationship between serum thyroid hormone levels and inter-
leukin-6 (IL-6), or tumor necrosis factor- (TNF- ) (10).
Because cytokines were operative in an extensive network, we
wondered if other cytokines are involved. Interleukin-8 (IL-8)
has been identified as a potent proinflammatory and inter-
leukin 10 (IL-10) as an anti-inflammatory cytokine (11, 12).
IL-10 is reported to block the production of proinflmamatory
cytokines in response to lipopolysaccharide or other stimuli
(13, 14). High IL-10 production in transplant recipients is
believed to have a major role in maintaining immunobalance
(15, 16). However, there have been scarce data on the role of
IL-8 and IL-10 in the pathogenesis of ESS (17). 
Thus, we intended to identify whether IL-8 and IL-10
could contribute to the development of ESS after BMT. We
also observed the effect of total body irradiation (TBI) and
high dose steroid therapy through the changes of thyroid
function and cytokine profiles after allogeneic BMT.
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Circulating IL-8 and IL-10 in Euthyroid Sick Syndromes following
Bone Marrow Transplantation 
It is generally agreed that euthyroid sick syndromes (ESS) are associated with an
increased production of cytokines. However, there has been scarce data on the
relationship thyroid hormone changes and cytokines among the patients undergoing
bone marrow transplantation (BMT). Because interleukin-8 (IL-8) has been iden-
tified as a potent proinflammatory and interleukin-10 (IL-10) as an antiinflammatory
cytokine, we studied the relation between thyroid hormone parameters and these
cytokines following BMT. We studied 80 patients undergoing allogeneic BMT.
Serum T3 decreased to nadir at post-BMT 3 weeks. Serum T4 was the lowest at
the post-BMT 3 months. Serum TSH sharply decreased to nadir at 1 week and
gradually recovered. Serum free T4 significantly increased during 3 weeks and
then returned to basal level. Mean levels of serum IL-8 significantly increased at
1 week after BMT. Mean levels of serum IL-10 significantly increased until 4 weeks
after BMT. No significant correlation was found between serum thyroid hormone
parameters and cytokines (IL-8, IL-10) after adjusting steroid doses during the
entire study period. In conclusion, ESS developed frequently following allogeneic
BMT and cytokine levels were increased in post-BMT patients. However, no sig-
nificant correlation was found between serum thyroid hormone parameters and
these cytokines. 
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MATERIALS AND METHODS 
Patients
We prospectively enrolled 80 patients (30 females, 50 males)
undergoing allogeneic BMT for hematologic diseases from
October 1998 to August 1999 in St. Mary’s Hospital in
Korea. Exclusion criteria were previous thyroid disease and
the use of thyroid hormones or thyrostatic medication before
BMT. Patients who died before 1 month after BMT were also
excluded. Underlying diseases among the 80 patients were
27 chronic myelogenous leukemia, 23 acute myelogenous
leukemia, 13 acute lymphoblastic leukemia, 8 severe aplastic
anemia, 7 myelodysplastic syndrome, 1 multiple myeloma,
and 1 paroxysmal nocturnal hemoglobinuria). The mean age
of the patients was 32.7±7.8 yr (mean±SD, range 19-54)
at the time of BMT. 
Fifty three patients received TBI (10-13.2 Gy) as a condi-
tioning regimen. Intravenous cyclosporin A, 5 mg/kg/day one
day before BMT and 3 mg/kg/day until the 20th day after
BMT, was administered to all patients in order to prevent graft
versus host disease (GVHD). Thereafter, oral cyclosporin A
at 6 mg/kg/day was begun and continued for 6-12 months.
Established GVHD was treated with a combination of intra-
venous methylprednisolone or oral prednisolone and cyclo-
sporin A. Doses were tapered when clinical control of GVHD
was achieved. Most patients received steroid as a premedica-
tion, when platelet transfusions were performed for the preven-
tion of bleeding owing to thrombocytopenia. Some patients
received high dose steroid therapy and oral prednisolone, so
this particular group of patients was classified as a high dose
steroid group (40 patients). The causes for the administration
of high dose steroid among the particular patients were GVHD
and BOOP (Bronchiolitis Obliterans Organizing Pneumo-
nia), and Pneumocystis carinii pneumonia. The mean dose of
prednisolone which was administered during post-BMT 1
month was 35.4±4.8 mg/day and 11.2±2.4 mg/day
among the high dose steroid group (n=40) and the non-high
dose steroid group (n=40), respectively. The high-dose steroid
group was arbitrarily defined as the patients with prednisolone
dose above the mean of 15 mg/day during post-BMT 1 month.
Blood was sampled from all patients to determine serum
levels of T3, T4, FT4, and TSH before BMT, at 1, 2, 3, 4 weeks
and 3, 6 months after BMT, respectively. From 24 out of the
80 patients, serum cytokines (IL-8, IL-10) were measured
before BMT, at 1, 2, 3, 4 weeks and 3 months after BMT. The
correlation of serum thyroid hormone levels and cytokines was
evaluated at each time point before, and serially after BMT.
Thyroid hormone parameters among the patients with TBI
or the high dose steroid group were compared to those in the
patients without TBI or high dose steroid therapy. We also
analyzed the incidence of ESS. Low T3 syndrome was defined
as serum T3 level is below normal range at any time point and
low T3, T4 syndrome was defined in which both serum T3 and
T3 are below normal range at any time point until post-
BMT 3 months. 
The protocol was approved by the Institutional Review Board
of St. Mary’s Hospital and informed consents were obtained
from all participants.
Methods
All assays were performed in serum samples. Serum T3 (RIA-
mat T3, Byk-Sangtec Diagnostica, Germany, normal values:
1.1-2.9 nmol/L) and serum T4 (RIA-mat T4, Byk-Sangtec
Diagnostica, Germany, normal values: 64-154 nmol/L) were
determined in duplication by radioimmunoassay. The intra-
and inter-assay coefficients of variation (CV) for the range of
concentrations evaluated were 3.0% and 5.0% for T3 and
2.8% and 5.1% for T4, respectively. Serum TSH (IRMA-mat
TSH, Byk-Sangtec Diagnostica, Germany, normal values: 0.3-
3.0 mU/L) was determined by immunoradiometric assay. The
intra-assay and inter-assay CV of TSH were 2.5% and 5.7%,
respectively. Serum FT4 (RIA-mat FT4, Byk-Sangtec Diagnos-
tica,Germany, normal values : 9-24 pmol/L) were determined in
duplication by radioimmunoassay. Intra-assay and Inter-assay
CV of FT4 were 2.4% and 7.8%.
ELISA was used to measure serum IL-8 and IL-10 (ELISA
kit, Hyundae Pharm. Institute, Incheon, Korea). The detection
limits for IL-8 and IL-10 were 10 and 10.4 pg/mL, respective-
ly. The maximum inter- and intra-assay CV for the range of
concentrations evaluated were 7.4% and 7.6% for IL-8 and
9.8% and 5.6% for IL-10. Blood samples were taken between
7 a.m. and 9 a.m. following an overnight fast. After centrifuga-
tion (1,500×g) for 10 min, aliquots of serum were stored at
-20℃until analysis.
Statistical analysis
All values are given as the mean±SEM. The data were
analyzed by ANOVA for repeated measures, followed by post-
hoc analysis for pairwise comparisons. Spearman rank test
was used to examine the bivariate correlations between two
variables. Significance was accepted at p<0.05. 
RESULTS
The serial changes of thyroid hormones levels after
BMT
The mean levels of serum T3, T4and TSH before BMT were
1.37±0.07 nmol/L, 79.4±3.3 nmol/L, 0.81±0.07 mU/L,
respectively. For all patients analyzed, mean levels of serum
TSH sharply decreased to nadir at 1 week (p<0.01 against
basal value), and gradually recovered until 6 months, at which
TSH level is not significantly different from basal values.
Mean levels of serum T3 decreased significantly at 1 week, andIL-8, IL-10 and Thyroid Function Following BMT 757
declined more until the nadir of 3 weeks (p<0.01 against basal
value). It began to increase after 4 weeks, and gradually reached
pre-BMT basal values until 6 months. Mean levels of serum T4
increased within normal range during initial 2 weeks follow-
ing BMT, but thereafter decreased significantly at 3 months
compared to basal values (p<0.05 against basal value). Then it
recovered to basal values at 6 months. Serum FT4 significant-
ly increased within normal range during 3 weeks following
BMT (p<0.01) and then returned to basal level until 3 months
(Fig. 1). Low T3 syndrome was found among 47 out of the 80
patients (58.8%), and low T3, T4syndrome was found in other
26 patients (32.5%).
The serial changes of serum cytokines (IL-8, IL-10)
after BMT
Mean levels of serum IL-8 significantly increased at 1 weeks
after BMT (p<0.05 vs baseline), and declined thereafter. Mean
levels of serum IL-10 significantly increased at 2, 3 and 4
weeks after BMT (p<0.01 vs baseline) and declined there-
after (Fig. 2).
The correlations between serum thyroid hormone lev-
els and serum cytokines (IL-8, IL-10) after BMT
Spearman rank test revealed no significant correlation be-
tween serum thyroid hormone parameters (T3, T4, FT4, TSH)
and cytokines (IL-8, IL-10) before BMT, and at 1, 2, 3, 4 weeks
and 3 months after BMT, respectively, except for 3 cases. There
were significant inverse relationships between IL-8 and T3 at
2 weeks (r=-0.48, p<0.05), IL-8 and FT4at 3 months (r=-0.83,
p<0.05), and IL-10 and T3at 1 week (r=-0.45, p<0.05), respec-
tively (Table 1). However, these relations became insignificant
after adjusting steroid doses.
The differences in thyroid hormone parameters between
the patients with and without TBI or high dose steroid
therapy
There were no significant differences in serum T3, T4 and
TSH levels between the patients with and without TBI except
for serum T4 levels at post-BMT 3 weeks. Serum TSH levels
in the patients with TBI tended to be lower than those with-
out TBI during the entire observation period, but without
statistical significance (Fig. 3A). Patients from both groups
did not display any differences in serum FT4 level during the
entire period. 
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Fig. 1. The serial changes of thyroid hormones and TSH levels
after BMT. Data are given as mean values (±SEM). *p<0.05 and
� p<0.01 against basal values. PB: pre-BMT, W: weeks, M: months.
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Fig. 2. The changes of serum IL-8 and IL-10 levels in peripheral
blood, before and after allogeneic BMT. Data is given as mean
values (±SEM). *p<0.05, 
� p<0.01 against basal value. Following
BMT, serum IL-8 increases at 1 week and declines thereafter.
Serum IL-10 increases reaching a peak at 4 weeks and also declin-
ing thereafter. PB: pre-BMT, W: weeks, M: months.
Time
IL-8 serum T3 0.33 -0.28 -0.48* 0.01 -0.02 0.26
(pg/mL) (nmol/L)
serum T4 0.27 0.11 0.08 0.08 -0.41 0.49
(nmol/L)
serum TSH -0.04 -0.24 -0.08 -0.07 -0.54 -0.26
(mU/L)
serum FT4 0.03 0.15 -0.07 0.27 -0.10 -0.83*
(pmol/L)
IL-10 serum T3 -0.16 -0.45* -0.30 -0.30 -0.29 -0.10
(pg/mL) (nmol/L)
serum T4 -0.23 -0.10 -0.28 -0.18 -0.57 -0.10
(nmol/L)
serum TSH 0.28 -0.16 0.1 0.10 -0.02 -0.67
(mU/L)
serum FT4 -0.21 -0.10 -0.24 -0.39 -0.31 0.21
(pmol/L)
*p <0.05
Pre-BMT   1 W   2 W   3 W   4 W   3 M
Table 1. Correlation coefficients between cytokine concentra-
tions (IL-8, IL-10) and thyroid hormone parameters following
BMT (Spearman rank test)
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Patients with high dose steroid represented lower levels of
T3 at 3 week (p<0.05), and TSH at 2 and 3 week (p<0.05)
than those with low dose steroid with statistical significance.
Serum T3, T4 and TSH levels in the patients with high dose
steroid tended to be lower than those with low dose steroid
during the entire period, but without significance (Fig. 3B).
Patients from both groups did not display any differences in
serum FT4 level during the entire period.
The differences in IL-8 and IL-10 levels between the pa-
tients with and without TBI or high dose steroid therapy
There were no significant differences in serum IL-8 and IL-10
levels between the patients with and without TBI during the
entire period (Fig. 4A). 
There were no significant differences in serum IL-8 and IL-
10 levels between the patients with high dose steroid therapy
and without it, except for serum IL-10 levels at 2 and 3 weeks
(Fig. 4B).
DISCUSSION
In this study, we found the rapid change of thyroid function
and IL-8, IL-10 following allogeneic BMT, and also observed
that thyroid hormone levels were not related with IL-8 and
IL-10. In a study of 27 patients undergoing BMT, serum TSH
and T3 levels decreased significantly at the first months after
BMT compared to basal values, but serum T4 levels declined
in less degree and more slowly than serum T3 levels (18). Our
data are in agreement with those reported previously (18, 19).
In general, serum TSH level in ESS is usually normal, but
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Fig. 3. The effects of TBI (A) and high dose steoid therapy (B) on thyroid function after BMT. Data are given as mean values (±SEM). *p<0.05
between TBI (+) and TBI (-) or S (+) and S (-). TBI (+): patients with TBI; TBI (-): patients without TBI. S (+): patients with high-dose steroid
therapy; S (-): patients without high-dose steroid therapy. PB: pre-BMT, W: weeks, M: months.
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often decreased or increased in ESS. In this study, serum TSH
decreased significantly during the early period of BMT, and
recovered gradually and spontaneously until 3 months. Initial
decrease of TSH might be related to the prednisolone therapy
and TBI-related hypothalamic dysfunction. It is noteworthy
that acute changes of T3 and T4 concentrations in these BMT
recipients gradually recovered to the pre-BMT levels at 6
months. This reversibility in thyroid function indicates that
acute changes in thyroid hormone levels in the early period of
the post-BMT represent only the reactive change in response
to BMT, confirming the presence of ESS. 
The incidence of ESS after BMT is reported to be 43% at
the post-BMT 3 months (20), but there has been no study
showing the serial changes of thyroid hormone parameters
during the earlier period of the post-BMT, during which more
development of ESS is expected to occur. In our study, total
91.3% patients had ESS during the post-BMT 6 months. Low
T3 syndrome was found in 58.8% patients and low T3, T4 syn-
drome in other 32.5% patients during 6 months after BMT.
It suggests that ESS develops frequently in the early period of
post-BMT, especially during the first month after BMT. 
IL-8 is well known pro-inflammatory cytokine, which is
involved in local and systemic inflammatory reactions includ-
ing GVHD or severe hepatic veno-occlusive disease (VOD)
(21, 22). In addition, IL-8 is abundantly produced by normal
hepatocytes. And endothelial injury occurring in the liver dur-
ing VOD may elevate systemic IL-8 concentrations (21).
Within the cytokine network, the activation of pro-inflam-
matory mediators is followed by the increased production of
endogenous inhibitory molecules, including the antagonistic
cytokines. The serum IL-10 concentration is correlated with
the production of inflammatory cytokines, such as IL-1, IL-6
and TNF- (13, 14). Indeed, systemic TNF- release during
pre-transplant conditioning, which was previously reported
to be an indicator of poor outcome, was inhibited among the
patients with high IL-10 production (15, 16, 23). IL-10 is a
Th2 cytokine that inhibits cytokine production by Th1 cell.
High spontaneous IL-10 production in transplant recipients is
associated with fewer transplant related complications. How-
ever, Hempel et al. reported that high IL-10 serum levels
among the patients after BMT were significantly associated
with a fatal outcome (24). There have been several studies
regarding the changes of thyroid function or cytokines follow-
ing BMT. Increased circulating cytokine levels are associated
with several complications of BMT, such as GVHD or infec-
tious episodes (25-27). However, there was no study regarding
the relation between thyroid hormone changes and cytokines
among the patients undergoing BMT, to our knowledge.
Because IL-8 has been identified as a potent pro-inflammatory
and IL-10 as an anti-inflammatory cytokine, we studied the
relation between serum concentration of thyroid hormone
parameters and these cytokines, and as a result, we observed
no significant correlation between serum thyroid hormone
parameters (T3, T4, TSH) and cytokines (IL-8, IL-10) before
BMT and during the 3 months following BMT. Boelen et al.
studied the level of IL-8 and IL-10 among the patients with
ESS and found no evidence that they had a pathologic role
(17), which was consistent with our result. It has been shown
that human thyrocytes can synthesize cytokines which activate
T and B lymphocytes. These immune cells play important roles
during the initiation and continuation of thyroid autoimmu-
nity. It was reported that cytokines (IL-6, sIL-6R, IL-8) could
play an important role in the development of Graves’ disease,
and that their levels are modulated by thyrostatic treatment
(28). In this study, it is interesting that serum IL-10 levels are
significantly higher at 2 and 3 weeks in the high dose steroid
group than the low dose group on the view point that immune
function and the production of inflammatory cytokines are
generally reduced by steroid treatment (29). IL-10 is known
to be higher in the patients with the post-BMT complications
(e.g. GVHD) (24, 30), thus larger amounts of steroid might
be administered to these complicated cases. We think that it
could explain why IL-10 levels were higher in the patients with
high dose steroid therapy. 
Our study implies that ESS develops frequently following
allogeneic BMT and these changes gradually recover until
post-BMT 3 months. Increased levels of cytokines, including
IL-8 and IL-10, were found among the post-BMT patients,
and no significant correlation was found between serum thy-
roid hormone parameters. 
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